Alzheimer's Disease

13 Drugs classified under this therapeutic system

Acetylcholinesterase Inhibitor. Donepezil HCl 5 mg, 10 mg.
F.C. TABS: 28. 1 x 5 mg or 10 mg tab 1 x
dly.
Mild to mod. dementia of Alzheimer’s
type.
C/I: Hypersens. to donepezil HCl or to
piperadine derivatives.

Acetylcholinesterase Inhibitor. Donepezil HCl 5 mg, 10 mg.
TABS.: 30. General., as a start. dosage 5 mg ×1/d at night before bed time. After one month, the dose may be incr. to 10 mg. The max. recomm. dosage is 10 mg each night. The tablet cannot be halved, as there is no score line.
Tmt. of mild- moder.  severe Alzheimer's dementia.
C/I: Hypersens. to active  subst., piperidine derivat.

NMDA Antagonist. Memantine HCl 10 mg.
TABS: 56. Max: 20 mg dly. Titrat. for
maint. dose by 5 mg/wk for first 3 wks:
1st wk: 5 mg dly (1/2 tab); 2nd wk: mg
1 x dly; 3rd wk: 15 mg 1 x dly.; 4th
wk: Cont. with maint. dose: 20 mg 1 x
dly. See lit.
Tmt. of pts. with moder.- sev. Alzheimer’s
dis.
C/I: Hypersens.

NMDA Antagonist. Memantine HCl 20 mg.
TABS: 28, 56. Max: 20 mg dly. Titrat. for
maint. dose by 5 mg/wk for first 3 wks:
1st wk: 5 mg dly (1/2 tab); 2nd wk: mg
1 x dly; 3rd wk: 15 mg 1 x dly.; 4th
wk: Cont. with maint. dose: 20 mg 1 x
dly. See lit.
Tmt. of pts. with moder.- sev. Alzheimer’s
dis.
C/I: Hypersens.

NMDA Antagonist. Memantine HCl 10 mg/g.
ORAL SOL.: 50 g x 5 mg pump
actuation. Recommend. maint. dose:
20 mg (4 pump actuats.) dly achieved
by upward titrat. of 5 mg/wk over 1st 3
wks as follows: 1st wk: 1 pump actuat.
1 x dly, 2nd wk: 2 pump actuats. 1 x
dly; 3rd wk: 3 pump actuats. 1 x dly;
4th week on: Max 4 pump actuats. 1 x
dly. Not recommend. child under 18
yrs. See lit.
Tmt. of pts. with moder.- sev. Alzheimer’s
dis.
C/I: Hypersens.

Acetylcholinesterase Inhibitor. Rivastigmine 1.5, 3, 4.5 , 6 mg.
CAPS: 28 x 1.5, 3, 4.5.
Initi. dose: 1.5 mg ×2/d., Pts. known to
be particul. sensit. to the effects of cholinerg. drugs should be start. at a dose of 1 mg ×2/d. Dose titrat. Init.: 1.5 mg×2/d. If this dose is well toler. after a minim. of 2 wks. of tmt., the dose may be incr. to 3 mg×2/d. Subseq. incr. to 4.5 mg and then 6 mg ×2/d based on good tolerab.  of the current dose and may
be consid. after a minim. of 2 wks. tmt.
at that dose level.
If adverse effects (e.g. naus., vomit.,
abd. pain, loss of appetite) wt. decr. are
observ. during tmt., these may
respond to omit. one or more doses. If
ADR effects persist, the dly. dose
should be reduced to the previous
well-tolerat. dose.
Re-init. of therapy: If tmt. is interrupt.
for longer than 3 d, tmt. should be
re-init. with 1.5 mg ×2/d and titrat. as
described above.
Mainten. dose: 1.5 mg -6 mg ×2/d; to
achieve max. therap. benefit pts. should
be maintain. on their highest well tolerated dose.
Recommend. max. dly. dose 6 mg ×2/a
Caps. should be admin. with morn.and even. meals.
Tmt. of pts. with mild – moder. sev. dement.
of the alzheimer type, also termed probable
alzheimer’s dis. or alzheimer’s dis. Symptom. tmt. of mild to moder. sev. alzheimer’s dement. Symptom. tmt. of mild – moder. sev. dementia assoc. with Parkinson’s dis.
C/I: Known hypersens. to rivastigmine,
to other carbamate derivat.
Prev. history of applicat. site react.
suggest. of allerg. contact dermatit. with
rivastigmine transderm. patch.